NCT07907991
The AIRWARD Study: A Study to Test Whether Verducatib Helps People With Chronic Obstructive Pulmonary Disease
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below.
- Minor Trial sites expanded: 0 → 26 locations
- Primary completion moved earlier from Dec 12, 2029 to Nov 12, 2029
- Study completion moved earlier from Jan 9, 2030 to Dec 10, 2029
- Study First Submitted
- Minor: routine updates
Endpoints
Primary
Annualised rate of moderate or severe acute exacerbation of chronic obstructive pulmonary disease (AECOPD) (number of events per person per year)
Timeframe: Up to week 76
Secondary (9)
Time to first moderate or severe AECOPD
Time to first severe AECOPD
Achievement of St George's Respiratory Questionnaire (SGRQ) response (decrease in total score by ≥4 points from baseline) at week 52
Absolute change from baseline in post-Bronchodilator (BD) forced expiratory volume in 1 second (FEV1) (milliliters) at week 52
Annualised rate of severe AECOPD
Show 4 moreShow less
Absolute change from baseline in SGRQ total score at week 52
Achievement of Evaluating Respiratory Symptoms E-RS: COPD response (decrease by ≥2 points from baseline) at week 52
Achievement of Chronic Airways Disease Assessment Test (CAAT) response (decrease by ≥2 points from baseline) at week 52
Absolute change from baseline in post-BD Forced expiratory volume in 1 second percent predicted (FEV1pp) at week 52
Arms and interventions
Verducatib treatment groupExperimental
Placebo groupPlacebo comparator
Drugs: Verducatib, Placebo matching verducatib
Sites
26 sites in 3 countries
United States 18, Italy 4, Malaysia 4